Resectable Hepatocellular Carcinoma Clinical Trial
Official title:
A Pre-Operative Study Evaluating Nivolumab Plus ADI-PEG 20 in Patients With Resectable Hepatocellular Carcinoma
This phase II trial studies the effect of nivolumab and ADI-PEG 20 before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ADI-PEG 20 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. Giving nivolumab and ADI-PEG 20 before surgery may help control liver cancer.
PRIMARY OBJECTIVE: I. To evaluate the safety and tolerability of therapy and assess the pathologic response rate including pathologic complete response (pCR) and degree of necrosis (> 50% in tumor volume) with nivolumab + pegargiminase (ADI-PEG 20) in resectable hepatocellular carcinoma (HCC) in the context of presurgical therapy. SECONDARY OBJECTIVE: I. To assess the efficacy of presurgical nivolumab + ADI-PEG 20 therapy in HCC by estimating the time-to-progression (TTP), recurrence-free survival (RFS), and overall survival (OS). EXPLORATORY OBJECTIVES: I. To assess the immunological/biomarker changes (pre- versus [vs] post-treatment) in tumor tissues and peripheral blood in response to nivolumab + ADI-PEG 20 in HCC therapy. II. To explore any potential association between these biomarker measures and antitumor response and immune-related response criteria (irRC) assessed by MD Anderson Department of Diagnostic Imaging. OUTLINE: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and pegargiminase intramuscularly (IM) at 2 days before day 1 of cycle 1, day 8 of cycle 1, days 1 and 8 of cycle 2, and day 1 of cycle 3. Treatments repeat every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection at week 7. After completion of study treatment, patients are followed up at 30 days, then every 12 weeks for up to 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT04856046 -
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
|
||
| Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04857684 -
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
|
Early Phase 1 | |
| Recruiting |
NCT04701060 -
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05578430 -
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
|
Phase 2 | |
| Recruiting |
NCT02379377 -
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
|
Phase 1 | |
| Recruiting |
NCT04721132 -
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
|
Phase 2 | |
| Completed |
NCT06013657 -
Surgical Resection for Hepatocellular Carcinoma
|
||
| Recruiting |
NCT05519410 -
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04834986 -
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05701488 -
SIRT With Tremelimumab and Durvalumab for Resectable HCC
|
Phase 1 | |
| Not yet recruiting |
NCT05807776 -
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
|
Phase 2 |